Roles for neuregulins in human cancer.

The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther (2008) 1.90

The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. Cancer Res (2009) 1.56

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res (2007) 1.08

An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation (2013) 1.06

Cancer invasion and metastasis: interacting ecosystems. Virchows Arch (2009) 1.05

ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.04

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks. Breast Cancer Res (2007) 1.02

Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J (2014) 0.99

Extracellular molecules involved in cancer cell invasion. Cancers (Basel) (2015) 0.85

Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β overexpression. J Natl Cancer Inst (2014) 0.83

Expression of NRG1 and its receptors in human bladder cancer. Br J Cancer (2011) 0.83

Global functional analysis of nucleophosmin in Taxol response, cancer, chromatin regulation, and ribosomal DNA transcription. Exp Cell Res (2006) 0.81

Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer. Proc Natl Acad Sci U S A (2012) 0.81

Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells. J Gastroenterol (2014) 0.78

Prognosis Relevance of Serum Cytokines in Pancreatic Cancer. Biomed Res Int (2015) 0.77

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88

Angiogenesis in cancer and other diseases. Nature (2000) 28.28

Rho GTPases and the actin cytoskeleton. Science (1998) 28.19

Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05

Oncogenic kinase signalling. Nature (2001) 16.30

The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 6.78

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science (1995) 6.37

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12

Multiple essential functions of neuregulin in development. Nature (1995) 5.66

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell (2002) 5.64

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol (2001) 5.59

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell (2002) 4.92

Neuregulins: functions, forms, and signaling strategies. Exp Cell Res (2003) 4.62

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A (1994) 4.51

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell (2003) 4.23

Identification of heregulin, a specific activator of p185erbB2. Science (1992) 4.17

Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature (2003) 3.61

Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature (1993) 3.42

The ErbB receptors and their role in cancer progression. Exp Cell Res (2003) 3.37

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A (1993) 3.36

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell (2003) 3.20

Structure of the extracellular region of HER3 reveals an interdomain tether. Science (2002) 3.19

The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res (2003) 3.18

Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci U S A (1990) 3.11

Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol (2001) 2.93

Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev (2004) 2.86

HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene (1995) 2.84

Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell (1992) 2.77

Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer (2000) 2.73

ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell (1993) 2.67

Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature (1993) 2.63

Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell (1992) 2.62

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer (2002) 2.44

Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys (2004) 2.41

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res (2000) 2.24

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res (2004) 2.15

Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol (1995) 2.13

Isoform-specific expression and function of neuregulin. Development (1997) 2.10

Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem (1998) 2.06

ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol (1999) 2.03

A role for LIM kinase in cancer invasion. Proc Natl Acad Sci U S A (2003) 2.03

ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer (1998) 1.98

Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol (2001) 1.96

Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J (1997) 1.91

Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res (1997) 1.91

Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol (1995) 1.91

Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature (1997) 1.90

Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A (1997) 1.89

A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature (2002) 1.89

Back signaling by the Nrg-1 intracellular domain. J Cell Biol (2003) 1.85

ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res (2003) 1.80

Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res (2000) 1.80

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer (2003) 1.67

The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. J Invest Dermatol (2003) 1.64

Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol Cell Biol (1994) 1.64

Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res (2003) 1.58

Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis. J Cell Biol (1998) 1.56

Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol (2003) 1.53

Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene (2003) 1.51

Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem (2001) 1.50

Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene (2000) 1.50

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol (2000) 1.47

The N-terminal region of neuregulin isoforms determines the accumulation of cell surface and released neuregulin ectodomain. J Biol Chem (2000) 1.45

Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature (1997) 1.43

Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res (1997) 1.41

Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli. Cell Growth Differ (1996) 1.39

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene (1999) 1.39

Signalling shortcuts: cell-surface receptors in the nucleus? Nat Rev Mol Cell Biol (2002) 1.39

Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. Mol Cell Neurosci (2000) 1.38

Role of morphogenetic factors in metastasis of mammary carcinoma cells. Oncogene (1998) 1.38

Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res (2000) 1.37

Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer (1997) 1.36

Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene (2002) 1.36

The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis (1999) 1.35

Roles of Meltrin beta /ADAM19 in the processing of neuregulin. J Biol Chem (2000) 1.35

Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene (1999) 1.34

The breast proto-oncogene, HRGalpha regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland. Oncogene (2002) 1.33

Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene (1999) 1.31

Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene (1999) 1.31

Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development. Proc Natl Acad Sci U S A (1994) 1.31

Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis (2003) 1.30

Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol (1999) 1.30

Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/beta -catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. J Biol Chem (2001) 1.30

Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins. J Biol Chem (2001) 1.29

Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem (2000) 1.29

Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21. Proc Natl Acad Sci U S A (1993) 1.28

ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene (1997) 1.28

Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am (1997) 1.28

NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene (1996) 1.27

Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors. Cancer Res (1993) 1.27

Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene (2001) 1.26

Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res (1996) 1.25

Pathogenesis of Paget's disease: epidermal heregulin-alpha, motility factor, and the HER receptor family. J Natl Cancer Inst (2000) 1.24

Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene (2002) 1.24

Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. J Pathol (2004) 1.23

Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci U S A (1998) 1.22

RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene (2000) 1.20

Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer (2008) 4.30

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat (2008) 2.59

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst (2009) 2.09

Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J (2004) 2.01

Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol (2008) 1.91

Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst (2010) 1.65

The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. J Invest Dermatol (2003) 1.64

Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J Nutr (2007) 1.38

Prenylated chalcone xanthohumol associates with histones in breast cancer cells--a novel target identified by a monoclonal antibody. Mol Nutr Food Res (2012) 1.38

EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol (2011) 1.32

An ex(o)citing machinery for invasive tumor growth. Cancer Res (2010) 1.31

Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res (2010) 1.30

A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas (2006) 1.29

Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) -- and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res (2005) 1.27

Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene (2004) 1.26

Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-beta or wounding. J Cell Sci (2004) 1.24

Soluble cadherins as cancer biomarkers. Clin Exp Metastasis (2007) 1.20

Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut (2012) 1.19

Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol (2007) 1.18

Modeling and quantification of cancer cell invasion through collagen type I matrices. Int J Dev Biol (2010) 1.17

Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro. Cancer Lett (2007) 1.11

Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion. Biol Chem (2002) 1.09

Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol (2010) 1.08

P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res (2004) 1.05

Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer. Int J Cancer (2005) 1.04

The secretory small GTPase Rab27B as a marker for breast cancer progression. Oncotarget (2010) 1.01

Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer. Int J Cancer (2013) 1.01

The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells. Int J Dev Biol (2011) 1.00

P-cadherin promotes cell-cell adhesion and counteracts invasion in human melanoma. Cancer Res (2005) 1.00

Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: a dietary intervention trial with fifty healthy post-menopausal Caucasian women. Br J Nutr (2007) 0.99

Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res (2005) 0.98

DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res (2012) 0.96

TRIP6, a novel molecular partner of the MAGI-1 scaffolding molecule, promotes invasiveness. FASEB J (2008) 0.96

Differential impact of TGF-beta and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion. Cancer Lett (2008) 0.95

Disposition of hop prenylflavonoids in human breast tissue. Mol Nutr Food Res (2010) 0.94

Differential secretome analysis of cancer-associated fibroblasts and bone marrow-derived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics (2013) 0.94

Resident and bone marrow-derived mesenchymal stem cells in head and neck squamous cell carcinoma. Oral Oncol (2010) 0.93

The tandem PDZ domains of syntenin promote cell invasion. Exp Cell Res (2007) 0.93

The HMI™ module: a new tool to study the Host-Microbiota Interaction in the human gastrointestinal tract in vitro. BMC Microbiol (2014) 0.92

Angiopoietin-like protein 4: health effects, modulating agents and structure-function relationships. Expert Rev Proteomics (2012) 0.92

Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion, and metastasis. PLoS One (2013) 0.92

Growth factor modulation of fibroblast proliferation, differentiation, and invasion: implications for tissue valve engineering. Tissue Eng (2006) 0.90

P-cadherin in adhesion and invasion: opposite roles in colon and bladder carcinoma. Int J Cancer (2011) 0.90

Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition. Oncogene (2004) 0.89

Bacterial monocultures, propionate, butyrate and H2O2 modulate the expression, secretion and structure of the fasting-induced adipose factor in gut epithelial cell lines. Environ Microbiol (2011) 0.88

Alpha-catenin is required for IGF-I-induced cellular migration but not invasion in human colonic cancer cells. Oncogene (2004) 0.87

Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia. Anticancer Res (2009) 0.86

Soluble N-cadherin in human biological fluids. Int J Cancer (2006) 0.86

Tumor grafts derived from sarcoma patients retain tumor morphology, viability, and invasion potential and indicate disease outcomes in the chick chorioallantoic membrane model. Cancer Lett (2012) 0.85

Compound A, a selective glucocorticoid receptor modulator, enhances heat shock protein Hsp70 gene promoter activation. PLoS One (2013) 0.84

Selective modulation of the glucocorticoid receptor can distinguish between transrepression of NF-κB and AP-1. Cell Mol Life Sci (2013) 0.84

The tumor ecosystem regulates the roads for invasion and metastasis. Clin Res Hepatol Gastroenterol (2011) 0.84

The in ovo CAM-assay as a xenograft model for sarcoma. J Vis Exp (2013) 0.83

Pollutant effects on genotoxic parameters and tumor-associated protein levels in adults: a cross sectional study. Environ Health (2008) 0.83

Cosupplementation of isoflavones, prenylflavonoids, and lignans alters human exposure to phytoestrogen-derived 17beta-estradiol equivalents. J Nutr (2009) 0.83

Disposition of soy isoflavones in normal human breast tissue. Am J Clin Nutr (2010) 0.83

Identification of a GαGβγ, AKT and PKCα signalome associated with invasive growth in two genetic models of human breast cancer cell epithelial-to-mesenchymal transition. Int J Oncol (2012) 0.82

Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene (2005) 0.82

Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment. Pharm Res (2012) 0.82

The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. Curr Pharm Des (2009) 0.82

Transport of hop bitter acids across intestinal Caco-2 cell monolayers. J Agric Food Chem (2010) 0.82

Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia. Leuk Res (2009) 0.82

Targeted liposome-loaded microbubbles for cell-specific ultrasound-triggered drug delivery. Small (2013) 0.81

P-cadherin counteracts myosin II-B function: implications in melanoma progression. Mol Cancer (2010) 0.81

Production of monoclonal antibodies against hop-derived (Humulus lupulus L.) prenylflavonoids and the development of immunoassays. Talanta (2011) 0.81

N-cadherin in neuroblastoma disease: expression and clinical significance. PLoS One (2012) 0.81

Colon cancer cells: pro-invasive signalling. Int J Biochem Cell Biol (2006) 0.81

The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities. Oncogene (2005) 0.81

Unraveling the mechanisms behind the enhanced MTT conversion by irradiated breast cancer cells. Radiat Res (2013) 0.81

An immunogen synthesis strategy for the development of specific anti-deoxynivalenol monoclonal antibodies. Food Addit Contam Part A Chem Anal Control Expo Risk Assess (2014) 0.81

Nerve growth factor mediates its pro-invasive effect in parallel with the release of a soluble E-cadherin fragment from breast cancer MCF-7/AZ cells. J Dairy Res (2005) 0.80

Down-regulation of myopodin expression reduces invasion and motility of PC-3 prostate cancer cells. Int J Oncol (2009) 0.80

On-chip light sheet illumination enables diagnostic size and concentration measurements of membrane vesicles in biofluids. Nanoscale (2014) 0.80

Unrecognized or potential risk factors for childhood cancer. Int J Occup Environ Health (2005) 0.80

Direct effects of delta opioid receptor agonists on invasion-associated activities of HCT-8/E11 colon cancer cells. Anticancer Res (2010) 0.80

Molecular targets of growth, differentiation, tissue integrity, and ectopic cell death in cancer cells. Cancer Biother Radiopharm (2005) 0.79

Bioavailability of hop-derived iso-α-acids and reduced derivatives. Food Funct (2011) 0.79

Bowes melanoma cells secrete heregulin, which can promote aggregation and counteract invasion of human mammary cancer cells. Int J Cancer (2005) 0.78

P-cadherin expression reduces melanoma growth, invasion, and responsiveness to growth factors in nude mice. Eur J Cancer Prev (2011) 0.78

Development of an oral mucosa model to study host-microbiome interactions during wound healing. Appl Microbiol Biotechnol (2014) 0.78

An immunohistochemical analysis of Rab27B distribution in fetal and adult tissue. Int J Dev Biol (2012) 0.78

Radiation-induced myosin IIA expression stimulates collagen type I matrix reorganization. Radiother Oncol (2013) 0.77

The microbial PhIP metabolite 7-hydroxy-5-methyl-3-phenyl-6,7,8,9-tetrahydropyrido[3',2':4,5]imidazo[1,2-a]pyrimidin-5-ium chloride (PhIP-M1) induces DNA damage, apoptosis and cell cycle arrest towards Caco-2 cells. Toxicol Lett (2008) 0.77

The flavonoid tangeretin activates the unfolded protein response and synergizes with imatinib in the erythroleukemia cell line K562. Mol Nutr Food Res (2010) 0.76

Estrogen receptor signaling is an unstable feature of the gonadotropic LbetaT2 cell line. Mol Cell Endocrinol (2007) 0.76

ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type. Leuk Res (2012) 0.76

Adherence and viability of intestinal bacteria to differentiated Caco-2 cells quantified by flow cytometry. J Microbiol Methods (2011) 0.76

From clinical observations of intensity-modulated radiotherapy to dedicated in vitro designs. Mutat Res (2010) 0.75

Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line. J Cell Physiol (2007) 0.75

An immobilized antibody targeting N-cadherin facilitates spread of N-cadherin-positive tumour cells. Anticancer Res (2012) 0.75

Cell aggregation on agar as an indicator for cell-matrix adhesion: effects of opioids. In Vitro Cell Dev Biol Anim (2009) 0.75

Enhancement of PDGF-BB mitogenic activity on human dermal fibroblasts by biospecific dextran derivatives. Biomaterials (2008) 0.75

When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts. Curr Drug Targets (2016) 0.75

Exploration of the SAR of anti-invasive chalcones: synthesis and biological evaluation of conformationally restricted analogues. Bioorg Med Chem (2012) 0.75